{
    "clinical_study": {
        "@rank": "149841", 
        "acronym": "OLYMPE", 
        "arm_group": {
            "arm_group_label": "Micafungin", 
            "description": "Patients affected with haemopathy (or affected with solid tumor for paediatric patients) under antifungal prophylaxis with micafungin."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this observational study is to describe the actual conditions of prescription\n      of micafungin in antifungal prophylaxis in French haematological and onco-haematological\n      units. The efficacy and the safety outcomes will be described."
        }, 
        "brief_title": "Use of Micafungin (Mycamine\u00ae) as Antifungal Prophylaxis in Haematology and Onco-haematology", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Antifungal Prophylaxis", 
            "Haemopathy"
        ], 
        "condition_browse": {
            "mesh_term": "Mycoses"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patient with haemopathy or paediatric patients with haemopathy or solid tumor.\n\n          -  Patient hospitalized in haematology, onco-haematology or onco-paediatrics unit.\n\n          -  Patient initiating antifungal prophylaxis with micafungin.\n\n        Exclusion Criteria:\n\n          -  Patient presenting documented fungal infection.\n\n          -  Patient already included in a biomedical study impacting the care management of\n             invasive fungal infection at the time of inclusion."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Hospitalized, adult patients with haemopathy or paediatric patients with haemopathy or\n        solid tumor, under antifungal prophylaxis with micafungin."
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02127788", 
            "org_study_id": "FR-MYC-NI-003"
        }, 
        "intervention": {
            "arm_group_label": "Micafungin", 
            "description": "intravenous", 
            "intervention_name": "Micafungin", 
            "intervention_type": "Drug", 
            "other_name": [
                "FK463", 
                "Mycamine"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antifungal Agents", 
                "Clotrimazole", 
                "Miconazole", 
                "Micafungin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Micafungin", 
            "Invasive Fungal Infection", 
            "Prophylaxis", 
            "Haematology", 
            "Observational study", 
            "France"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "number_of_groups": "1", 
        "official_title": "National, Longitudinal, Multicentre and Prospective, Observational Study of the Use of Micafungin (Mycamine\u00ae) in Antifungal Prophylaxis of Invasive Fungal Infections in Medical Practice in Haematology and Onco-haematology", 
        "overall_contact": {
            "email": "contact@nl.astellas.com", 
            "last_name": "Medical & Clinical Operations Department", 
            "phone": "+31 (0)71 5455050"
        }, 
        "overall_official": {
            "affiliation": "Astellas Pharma S.A.S.", 
            "last_name": "Medical and Scientific Affairs Manager, Infectious Diseases", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: The Commission nationale de l\u2019informatique et des libert\u00e9s", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "EORTC/MSG : European Organization for Research and Treatment of Cancer/ Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group", 
            "measure": "Breakthrough incidence of Invasive Fungal Infection (IFI), defined according to the revised EORTC/MSG criteria, during prophylaxis use of micafungin", 
            "safety_issue": "No", 
            "time_frame": "Up to 3 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02127788"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Odds ratio and 95% CI for each identified risk factors", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 months"
            }, 
            {
                "measure": "Incidence of IFI, defined according to the revised EORTC/MSG criteria", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 months"
            }, 
            {
                "measure": "Characteristics of patients treated with micafungin", 
                "safety_issue": "No", 
                "time_frame": "Day 0 (start of prophylaxis)"
            }, 
            {
                "description": "dose and administration pattern, temporary interruptions and treatment duration, oral treatment take-over", 
                "measure": "Conditions of use of micafungin", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 months"
            }, 
            {
                "measure": "Description of adverse events (AE) and serious adverse events (SAE)", 
                "safety_issue": "No", 
                "time_frame": "Up to 3 months"
            }, 
            {
                "description": "participating physicians (age, status, specialty), type of institution, location , type of unit, size of unit", 
                "measure": "Characteristics of units", 
                "safety_issue": "No", 
                "time_frame": "Day 0"
            }
        ], 
        "source": "Astellas Pharma Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Astellas Pharma S.A.S.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}